Cargando…
A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates
Despite tremendous efforts in the field of targeted cancer therapy with antibody–drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of target, antibody, and toxin, with little focus on the nature of the linker. We show here th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698870/ https://www.ncbi.nlm.nih.gov/pubmed/31544864 http://dx.doi.org/10.3390/antib7010012 |
_version_ | 1783444632291508224 |
---|---|
author | Verkade, Jorge M. M. Wijdeven, Marloes A. van Geel, Remon Janssen, Brian M. G. van Berkel, Sander S. van Delft, Floris L. |
author_facet | Verkade, Jorge M. M. Wijdeven, Marloes A. van Geel, Remon Janssen, Brian M. G. van Berkel, Sander S. van Delft, Floris L. |
author_sort | Verkade, Jorge M. M. |
collection | PubMed |
description | Despite tremendous efforts in the field of targeted cancer therapy with antibody–drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of target, antibody, and toxin, with little focus on the nature of the linker. We show here that a short and polar sulfamide spacer (HydraSpace™, Oss, The Netherlands) positively impacts ADC properties in various ways: (a) efficiency of conjugation; (b) stability; and (c) therapeutic index. Different ADC formats are explored in terms of drug-to-antibody ratios (DAR2, DAR4) and we describe the generation of a DAR4 ADC by site-specific attachment of a bivalent linker–payload construct to a single conjugation site in the antibody. A head-to-head comparison of HydraSpace™-containing DAR4 ADCs to marketed drugs, derived from the same antibody and toxic payload components, indicated a significant improvement in both the efficacy and safety of several vivo models, corroborated by in-depth pharmacokinetic analysis. Taken together, HydraSpace™ technology based on a polar sulfamide spacer provides significant improvement in manufacturability, stability, and ADC design, and is a powerful platform to enable next-generation ADCs with enhanced therapeutic index. |
format | Online Article Text |
id | pubmed-6698870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66988702019-09-05 A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates Verkade, Jorge M. M. Wijdeven, Marloes A. van Geel, Remon Janssen, Brian M. G. van Berkel, Sander S. van Delft, Floris L. Antibodies (Basel) Article Despite tremendous efforts in the field of targeted cancer therapy with antibody–drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of target, antibody, and toxin, with little focus on the nature of the linker. We show here that a short and polar sulfamide spacer (HydraSpace™, Oss, The Netherlands) positively impacts ADC properties in various ways: (a) efficiency of conjugation; (b) stability; and (c) therapeutic index. Different ADC formats are explored in terms of drug-to-antibody ratios (DAR2, DAR4) and we describe the generation of a DAR4 ADC by site-specific attachment of a bivalent linker–payload construct to a single conjugation site in the antibody. A head-to-head comparison of HydraSpace™-containing DAR4 ADCs to marketed drugs, derived from the same antibody and toxic payload components, indicated a significant improvement in both the efficacy and safety of several vivo models, corroborated by in-depth pharmacokinetic analysis. Taken together, HydraSpace™ technology based on a polar sulfamide spacer provides significant improvement in manufacturability, stability, and ADC design, and is a powerful platform to enable next-generation ADCs with enhanced therapeutic index. MDPI 2018-02-20 /pmc/articles/PMC6698870/ /pubmed/31544864 http://dx.doi.org/10.3390/antib7010012 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Verkade, Jorge M. M. Wijdeven, Marloes A. van Geel, Remon Janssen, Brian M. G. van Berkel, Sander S. van Delft, Floris L. A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates |
title | A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates |
title_full | A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates |
title_fullStr | A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates |
title_full_unstemmed | A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates |
title_short | A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates |
title_sort | polar sulfamide spacer significantly enhances the manufacturability, stability, and therapeutic index of antibody–drug conjugates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698870/ https://www.ncbi.nlm.nih.gov/pubmed/31544864 http://dx.doi.org/10.3390/antib7010012 |
work_keys_str_mv | AT verkadejorgemm apolarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT wijdevenmarloesa apolarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT vangeelremon apolarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT janssenbrianmg apolarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT vanberkelsanders apolarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT vandelftflorisl apolarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT verkadejorgemm polarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT wijdevenmarloesa polarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT vangeelremon polarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT janssenbrianmg polarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT vanberkelsanders polarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates AT vandelftflorisl polarsulfamidespacersignificantlyenhancesthemanufacturabilitystabilityandtherapeuticindexofantibodydrugconjugates |